Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report

Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zakaria Maat, Kamran Mushtaq, Mohamed A. Yassin
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	colitis chronic myeloid leukemia dasatinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7fb3f050297a4c249b0e5b71cb52312b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7fb3f050297a4c249b0e5b71cb52312b
record_format	dspace
spelling	oai:doaj.org-article:7fb3f050297a4c249b0e5b71cb52312b2021-11-11T10:40:45ZDasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report1662-657510.1159/000516794https://doaj.org/article/7fb3f050297a4c249b0e5b71cb52312b2021-10-01T00:00:00Zhttps://www.karger.com/Article/FullText/516794https://doaj.org/toc/1662-6575Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance to prior therapy including imatinib and in adults with Ph+ acute lymphoblastic leukemia. Common adverse reactions (>15%) in patients diagnosed with CP-CML include myelosuppression, fluid retention, and diarrhea. We report a 34-year-old Filipino female patient who received dasatinib as upfront therapy for the treatment of CP-CML who experienced chronic diarrhea for 2 months, which progressed to colitis.Zakaria MaatKamran MushtaqMohamed A. YassinKarger Publishersarticlecolitischronic myeloid leukemiadasatinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1441-1446 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	colitis chronic myeloid leukemia dasatinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	colitis chronic myeloid leukemia dasatinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Zakaria Maat Kamran Mushtaq Mohamed A. Yassin Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
description	Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance to prior therapy including imatinib and in adults with Ph+ acute lymphoblastic leukemia. Common adverse reactions (>15%) in patients diagnosed with CP-CML include myelosuppression, fluid retention, and diarrhea. We report a 34-year-old Filipino female patient who received dasatinib as upfront therapy for the treatment of CP-CML who experienced chronic diarrhea for 2 months, which progressed to colitis.
format	article
author	Zakaria Maat Kamran Mushtaq Mohamed A. Yassin
author_facet	Zakaria Maat Kamran Mushtaq Mohamed A. Yassin
author_sort	Zakaria Maat
title	Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_short	Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_full	Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_fullStr	Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_full_unstemmed	Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_sort	dasatinib-induced colitis with rectal sparing in a patient with chronic myeloid leukemia (chronic phase) on dasatinib as an upfront therapy: case report
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/7fb3f050297a4c249b0e5b71cb52312b
work_keys_str_mv	AT zakariamaat dasatinibinducedcolitiswithrectalsparinginapatientwithchronicmyeloidleukemiachronicphaseondasatinibasanupfronttherapycasereport AT kamranmushtaq dasatinibinducedcolitiswithrectalsparinginapatientwithchronicmyeloidleukemiachronicphaseondasatinibasanupfronttherapycasereport AT mohamedayassin dasatinibinducedcolitiswithrectalsparinginapatientwithchronicmyeloidleukemiachronicphaseondasatinibasanupfronttherapycasereport
_version_	1718439142372671488

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report

Ejemplares similares